<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002466</url>
  </required_header>
  <id_info>
    <org_study_id>90-062</org_study_id>
    <secondary_id>CDR0000076464</secondary_id>
    <secondary_id>NYU-97-6</secondary_id>
    <secondary_id>NCI-V90-0126</secondary_id>
    <nct_id>NCT00002466</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer</brief_title>
  <official_title>Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug or combining chemotherapy with
      radiation therapy may kill more tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by
      radiation therapy in treating patients with peripheral neuroectodermal tumors, Ewing's
      sarcoma, Wilms' tumor, or bone cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the response rate and event-free survival of patients with
      peripheral primitive neuroectodermal tumors or Ewing's sarcoma treated with cyclophosphamide,
      doxorubicin, vincristine, etoposide, and ifosfamide, followed by surgery (if feasible) and
      radiotherapy. II. Determine the response to a uniform treatment regimen in order to clarify
      whether these disease categories each have a different prognosis.

      OUTLINE: Patients are stratified according to disease category (primitive neuroectodermal
      tumor vs Ewing's sarcoma). Patients receive treatment on regimen A as outlined below during
      courses 1-3 and 6 and regimen B as outlined below during courses 4, 5, and 7 in the absence
      of disease progression or unacceptable toxicity. Each course lasts 3-4 weeks. Patients
      without metastatic disease after completion of course 3 undergo complete tumor resection, if
      feasible. Patients achieving complete response with or without microscopic residual disease
      after completion of course 7 undergo radiotherapy twice daily, 5 days a week, for 3 weeks.
      Patients with gross residual disease after completion of course 7 undergo radiotherapy twice
      daily, 5 days a week, for 3.6 weeks. Regimens A and B are defined below: Regimen A: Patients
      receive cyclophosphamide IV over 6 hours on days 1 and 2, doxorubicin IV continuously and
      vincristine IV continuously on days 1-3, and vincristine IV on day 9. Regimen B: Patients
      receive etoposide IV over 1 hour, followed immediately by ifosfamide IV over 1 hour on days
      1-5. Patients are followed monthly for 18 months and then every 6 months for 18 months.

      PROJECTED ACCRUAL: A maximum of 50 patients (25 per stratum) will be accrued for this study
      within 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1990</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Kidney Cancer</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Diagnosis of peripheral primitive neuroectodermal tumor, including
        peripheral neuroepithelioma or Askin tumor OR Diagnosis of localized or metastatic Ewing's
        sarcoma, including the following: Unresectable or metastatic small cell osteosarcoma
        Unresectable or metastatic other nonrhabdomyosarcomatous soft-tissue sarcomas Unresectable
        or metastatic other non-osteosarcomatous bone sarcomas Desmoplastic small round-cell tumor
        Metastatic or non-metastatic Wilms' tumor Immunocytochemistry, electron microscopy, and/or
        chromosomal analysis may be required to rule out other small round cell neoplasms

        PATIENT CHARACTERISTICS: Age: Any age Performance status: Not specified Life expectancy:
        Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified

        PRIOR CONCURRENT THERAPY: Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian H. Kushner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kushner BH, LaQuaglia MP, Wollner N, Meyers PA, Lindsley KL, Ghavimi F, Merchant TE, Boulad F, Cheung NK, Bonilla MA, Crouch G, Kelleher JF Jr, Steinherz PG, Gerald WL. Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol. 1996 May;14(5):1526-31.</citation>
    <PMID>8622067</PMID>
  </results_reference>
  <results_reference>
    <citation>Kushner BH, LaQuaglia MP, Wollner N, et al.: Desmoplastic small cell tumor (DSCT): prolonged progression-free survival with aggressive multi-modality therapy. [Abstract] Proceedings of the American Society of Clinical Oncology 14: A-1414, 443, 1995.</citation>
  </results_reference>
  <results_reference>
    <citation>Kushner BH, Meyers PA, Gerald WL, Healey JH, La Quaglia MP, Boland P, Wollner N, Casper ES, Aledo A, Heller G, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J Clin Oncol. 1995 Nov;13(11):2796-804.</citation>
    <PMID>7595741</PMID>
  </results_reference>
  <results_reference>
    <citation>Meyers PA, Gardner S, Lindsley K, et al.: High-risk Ewing's sarcoma (ES)/primitive neuroectodermal tumor (PNET) of bone: consolidation with total body irradiation (TBI), melphalan, and autologous stem cell reconstitution. [Abstract] Proceedings of the American Society of Clinical Oncology 14: A-1447, 451, 1995.</citation>
  </results_reference>
  <results_reference>
    <citation>Kushner BH, Meyers PA, Cheung NK, et al.: Very high-dose short-term chemotherapy for poor-risk solid tumors in children and young adults. [Abstract] Proceedings of the American Society of Clinical Oncology 12: A-1416, 413, 1993.</citation>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 23, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2004</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>localized osteosarcoma</keyword>
  <keyword>metastatic osteosarcoma</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>stage III Wilms tumor</keyword>
  <keyword>stage IV Wilms tumor</keyword>
  <keyword>nonmetastatic childhood soft tissue sarcoma</keyword>
  <keyword>metastatic childhood soft tissue sarcoma</keyword>
  <keyword>childhood desmoplastic small round cell tumor</keyword>
  <keyword>localized Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>Askin tumor</keyword>
  <keyword>peripheral primitive neuroectodermal tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Wilms Tumor</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

